These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Expression and clinical significance of interleukin-6 pathway in cholangiocarcinoma. Gu D; Zhao X; Song J; Xiao J; Zhang L; Deng G; Li D Front Immunol; 2024; 15():1374967. PubMed ID: 38881895 [TBL] [Abstract][Full Text] [Related]
3. Gankyrin promotes tumor growth and metastasis through activation of IL-6/STAT3 signaling in human cholangiocarcinoma. Zheng T; Hong X; Wang J; Pei T; Liang Y; Yin D; Song R; Song X; Lu Z; Qi S; Liu J; Sun B; Xie C; Pan S; Li Y; Luo X; Li S; Fang X; Bhatta N; Jiang H; Liu L Hepatology; 2014 Mar; 59(3):935-46. PubMed ID: 24037855 [TBL] [Abstract][Full Text] [Related]
4. Genome-wide screen identified let-7c/miR-99a/miR-125b regulating tumor progression and stem-like properties in cholangiocarcinoma. Lin KY; Ye H; Han BW; Wang WT; Wei PP; He B; Li XJ; Chen YQ Oncogene; 2016 Jun; 35(26):3376-86. PubMed ID: 26455324 [TBL] [Abstract][Full Text] [Related]
5. Inhibition of classic signaling is a novel function of soluble glycoprotein 130 (sgp130), which is controlled by the ratio of interleukin 6 and soluble interleukin 6 receptor. Garbers C; Thaiss W; Jones GW; Waetzig GH; Lorenzen I; Guilhot F; Lissilaa R; Ferlin WG; Grötzinger J; Jones SA; Rose-John S; Scheller J J Biol Chem; 2011 Dec; 286(50):42959-70. PubMed ID: 21990364 [TBL] [Abstract][Full Text] [Related]
6. Antitumor effects of interleukin-6 (IL-6)/interleukin-6 receptor (IL-6R) signaling pathway inhibition in clear cell carcinoma of the ovary. Yanaihara N; Hirata Y; Yamaguchi N; Noguchi Y; Saito M; Nagata C; Takakura S; Yamada K; Okamoto A Mol Carcinog; 2016 May; 55(5):832-41. PubMed ID: 25856562 [TBL] [Abstract][Full Text] [Related]
7. IL-6 trans-signaling in formation and progression of malignant ascites in ovarian cancer. Lo CW; Chen MW; Hsiao M; Wang S; Chen CA; Hsiao SM; Chang JS; Lai TC; Rose-John S; Kuo ML; Wei LH Cancer Res; 2011 Jan; 71(2):424-34. PubMed ID: 21123455 [TBL] [Abstract][Full Text] [Related]
8. Inhibition of interleukin-6 trans-signaling prevents inflammation and endothelial barrier disruption in retinal endothelial cells. Valle ML; Dworshak J; Sharma A; Ibrahim AS; Al-Shabrawey M; Sharma S Exp Eye Res; 2019 Jan; 178():27-36. PubMed ID: 30240585 [TBL] [Abstract][Full Text] [Related]
9. Increased activation of PI3K/AKT signaling pathway is associated with cholangiocarcinoma metastasis and PI3K/mTOR inhibition presents a possible therapeutic strategy. Yothaisong S; Dokduang H; Techasen A; Namwat N; Yongvanit P; Bhudhisawasdi V; Puapairoj A; Riggins GJ; Loilome W Tumour Biol; 2013 Dec; 34(6):3637-48. PubMed ID: 23832540 [TBL] [Abstract][Full Text] [Related]
10. Therapeutic blockade of the interleukin-6 receptor (IL-6R) allows sIL-6R generation by proteolytic cleavage. Prenissl N; Lokau J; Rose-John S; Haybaeck J; Garbers C Cytokine; 2019 Feb; 114():1-5. PubMed ID: 30557809 [TBL] [Abstract][Full Text] [Related]
11. MiR-124 induces autophagy-related cell death in cholangiocarcinoma cells through direct targeting of the EZH2-STAT3 signaling axis. Ma J; Weng L; Wang Z; Jia Y; Liu B; Wu S; Cao Y; Sun X; Yin X; Shang M; Mao A Exp Cell Res; 2018 May; 366(2):103-113. PubMed ID: 29530475 [TBL] [Abstract][Full Text] [Related]
12. Induction of phosphatase shatterproof 2 by evodiamine suppresses the proliferation and invasion of human cholangiocarcinoma. Zhu B; Zhao L; Liu Y; Jin Y; Feng J; Zhao F; Sun J; Geng R; Wei Y Int J Biochem Cell Biol; 2019 Mar; 108():98-110. PubMed ID: 30682488 [TBL] [Abstract][Full Text] [Related]
13. Allicin Inhibits Proliferation and Invasion in Vitro and in Vivo via SHP-1-Mediated STAT3 Signaling in Cholangiocarcinoma. Chen H; Zhu B; Zhao L; Liu Y; Zhao F; Feng J; Jin Y; Sun J; Geng R; Wei Y Cell Physiol Biochem; 2018; 47(2):641-653. PubMed ID: 29794468 [TBL] [Abstract][Full Text] [Related]
14. Luteolin arrests cell cycling, induces apoptosis and inhibits the JAK/STAT3 pathway in human cholangiocarcinoma cells. Aneknan P; Kukongviriyapan V; Prawan A; Kongpetch S; Sripa B; Senggunprai L Asian Pac J Cancer Prev; 2014; 15(12):5071-6. PubMed ID: 24998588 [TBL] [Abstract][Full Text] [Related]
15. Homophilic Interaction of CD147 Promotes IL-6-Mediated Cholangiocarcinoma Invasion via the NF-κB-Dependent Pathway. Dana P; Kariya R; Lert-Itthiporn W; Seubwai W; Saisomboon S; Wongkham C; Okada S; Wongkham S; Vaeteewoottacharn K Int J Mol Sci; 2021 Dec; 22(24):. PubMed ID: 34948304 [TBL] [Abstract][Full Text] [Related]
16. Knockdown of tripartite motif 59 (TRIM59) inhibits proliferation in cholangiocarcinoma via the PI3K/AKT/mTOR signalling pathway. Shen H; Zhang J; Zhang Y; Feng Q; Wang H; Li G; Jiang W; Li X Gene; 2019 May; 698():50-60. PubMed ID: 30822475 [TBL] [Abstract][Full Text] [Related]
17. Liraglutide exhibits potential anti-tumor effects on the progression of intrahepatic cholangiocarcinoma, in vitro and in vivo. Trakoonsenathong R; Kunprom W; Aphivatanasiri C; Yueangchantuek P; Pimkeeree P; Sorin S; Khawkhiaw K; Chiu CF; Okada S; Wongkham S; Saengboonmee C Sci Rep; 2024 Jun; 14(1):13726. PubMed ID: 38877189 [TBL] [Abstract][Full Text] [Related]
18. TGF-β pathway activation by idiopathic pulmonary fibrosis (IPF) fibroblast derived soluble factors is mediated by IL-6 trans-signaling. Epstein Shochet G; Brook E; Bardenstein-Wald B; Shitrit D Respir Res; 2020 Feb; 21(1):56. PubMed ID: 32070329 [TBL] [Abstract][Full Text] [Related]
19. Effect of transforming growth factor-beta1 on human intrahepatic cholangiocarcinoma cell growth. Shimizu T; Yokomuro S; Mizuguchi Y; Kawahigashi Y; Arima Y; Taniai N; Mamada Y; Yoshida H; Akimaru K; Tajiri T World J Gastroenterol; 2006 Oct; 12(39):6316-24. PubMed ID: 17072955 [TBL] [Abstract][Full Text] [Related]
20. The Soluble Interleukin 6 Receptor: Advanced Therapeutic Options in Inflammation. Rose-John S Clin Pharmacol Ther; 2017 Oct; 102(4):591-598. PubMed ID: 28675418 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]